LEVADEX Trademark

Trademark Overview


On Wednesday, February 8, 2017, a trademark application was filed for LEVADEX with the United States Patent and Trademark Office. The USPTO has given the LEVADEX trademark a serial number of 87329251. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 7, 2020. This trademark is owned by Allergan, Inc.. The LEVADEX trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
levadex

General Information


Serial Number87329251
Word MarkLEVADEX
Filing DateWednesday, February 8, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 7, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 6, 2017

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body; excluding vitamins and minerals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 14, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIrvine, CA 92612

Party NameAllergan, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Tuesday, September 8, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 7, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, January 24, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 23, 2020EXTENSION 5 GRANTED
Tuesday, January 21, 2020EXTENSION 5 FILED
Thursday, January 23, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, January 21, 2020TEAS EXTENSION RECEIVED
Thursday, June 20, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2019EXTENSION 4 GRANTED
Tuesday, June 18, 2019EXTENSION 4 FILED
Tuesday, June 18, 2019TEAS EXTENSION RECEIVED
Tuesday, January 29, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 25, 2019EXTENSION 3 GRANTED
Friday, January 25, 2019EXTENSION 3 FILED
Friday, January 25, 2019TEAS EXTENSION RECEIVED
Tuesday, July 24, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 20, 2018EXTENSION 2 GRANTED
Friday, July 20, 2018EXTENSION 2 FILED
Friday, July 20, 2018TEAS EXTENSION RECEIVED
Saturday, January 20, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 18, 2018EXTENSION 1 GRANTED
Thursday, January 18, 2018EXTENSION 1 FILED
Thursday, January 18, 2018TEAS EXTENSION RECEIVED
Tuesday, August 1, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 6, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2017PUBLISHED FOR OPPOSITION
Wednesday, May 17, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 27, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 24, 2017ASSIGNED TO EXAMINER
Thursday, March 16, 2017TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Thursday, March 16, 2017TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, February 14, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, February 13, 2017NEW APPLICATION ENTERED IN TRAM